A meta-analysis of the risk of hematological adverse events (AEs) associated with the use of PARP inhibitors in patients treated from cancer has been conducted.
Eligible publications included phase II and III randomized trials of patients treated from cancer with PARP inhibitors, describing events of all-grade and high-grade hematological toxicity which include (anemia, thrombocytopenia, neutropenia, and lymphopenia).
Our search strategy yielded 143 potentially eligible citations from pubmed/MEDLINE, google scholar, clinical trials.gov, ASCO and ESMO meetings library. Ineligible studies were excluded, and a total of 15 RCTs were involved in this analysis, 13 of them were phase 2 trials and only two were phase 3 trials, with a total of 3019 patients. The relative risk was 1.40 [95% confidence interval (CI): 1.26-1.55; p
Our analysis provided evidence that the use of PARP inhibitors is associated with an increased risk of all-grade and high-grade anemia, thrombocytopenia, neutropenia and lymphopenia compared with chemotherapy or placebo controls.
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.